Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part

被引：0

作者：

Cortes, J. ^{[1
,2
]}

Martinez Janesz, N. ^{[1
]}

Sablin, M. P. ^{[3
]}

Perez-Fidalgo, J. A. ^{[4
]}

Neven, P. ^{[5
]}

Hedayati, E. ^{[6
,7
]}

Ballester, A. ^{[8
]}

Ehrhart, M. P. ^{[9
,10
]}

Huang, D. Chin-Lun ^{[11
]}

Bogenrieder, T. ^{[12
]}

Schmid, P. ^{[13
]}

机构：

[1] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain

[2] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain

[3] Inst Curie, Dept Med Oncol, Paris, France

[4] Hosp Clin Univ Valencia, Dept Haematol & Med Oncol, Valencia, Spain

[5] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium

[6] Karolinska Inst, Stockholm, Sweden

[7] Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden

[8] Boehringer Ingelheim Espana SA, Dept Med Oncol, Barcelona, Spain

[9] Staburo GmbH, Munich, Germany

[10] Boehringer Ingelheim Pharma GmbH & Co KG, St Joseph, MO USA

[11] Boehringer Ingelheim Taiwan Ltd, Med, Taipei, Taiwan

[12] Boehringer Ingelheim RCV, Med, Vienna, Austria

[13] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England

来源：

EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

389

引用

页码：S112 / S112

页数：1

共 50 条

[41] Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
Chan, Arlene
Day, Daphne
Hui, Rina
McCarthy, Nicole
Wilson, Rosalind
Faltaos, Demiana
Shaw, Morena
Murphy, Caitlin
CANCER RESEARCH, 2023, 83 (05)
[42] Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study
Okusaka, Takuji
Ikeda, Masafumi
Fukutomi, Akira
Kobayashi, Yoshikazu
Shibayama, Kazuhiro
Takubo, Takatoshi
Gansert, Jennifer
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (05) : 442 - 447
[43] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
Hamilton, Erika
Pusztai, Lajos
Soliman, Hatem H.
Hurvitz, Sara
Grzegorzewski, Krzysztof
Habboubi, Nassir
Marreddy, Priya
Sahmoud, Tarek
Ibrahim, Nuhad
CANCER RESEARCH, 2023, 83 (05)
[44] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Bachelot, Thomas
Bourgier, Celine
Cropet, Claire
Ray-Coquard, Isabelle
Ferrero, Jean-Marc
Freyer, Gilles
Abadie-Lacourtoisie, Sophie
Eymard, Jean-Christophe
Debled, Marc
Spaeth, Dominique
Legouffe, Eric
Allouache, Djelila
El Kouri, Claude
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) : 2718 - 2724
[45] Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer A Phase 1b Clinical Trial
Juric, Dejan
Janku, Filip
Rodon, Jordi
Burris, Howard A.
Mayer, Ingrid A.
Schuler, Martin
Seggewiss-Bernhardt, Ruth
Gil-Martin, Marta
Middleton, Mark R.
Baselga, Jose
Bootle, Douglas
Demanse, David
Blumenstein, Lars
Schumacher, Karl
Huang, Alan
Quadt, Cornelia
Rugo, Hope S.
JAMA ONCOLOGY, 2019, 5 (02)
[46] XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.
Schmid, Peter
Rugo, Hope S.
Cortes, Javier
Huang, Chin-Lun
Crossley, Kate
Massey, Dan
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[47] Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study
Rugo, Hope S.
O'Shaughnessy, Joyce
Cortes, Javier
Bardia, Aditya
Hamilton, Erika P.
Hurvitz, Sara A.
Kaklamani, Virginia G.
Romero, Paula Munoz
Vallespir, Bartomeu Piza
Wasserman, Tomer
Theall, Kathy Puyana
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Kaufman, Bella
Mackey, John R.
Clemens, Michael R.
Bapsy, Poonamalle P.
Vaid, Ashok
Wardley, Andrew
Tjulandin, Sergei
Jahn, Michaela
Lehle, Michaela
Feyereislova, Andrea
Revil, Cedric
Jones, Alison
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5529 - 5537
[49] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara
Loibl, Sibylle
Tolaney, Sara
Kaklamani, Virginia
Tonini, Giulia
Matheny, Shannon
Theall, Kathy Puvana
O'Shaughnessy, Joyce
CANCER RESEARCH, 2024, 84 (09)
[50] XENERA™-1: A phase II trial of xentuzumab (Xe) in combinationwith everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement
Schmid, Peter
Rugo, Hope S.
Cortes, Javier
Huang, Dennis Chin-Lun
Crossley, Kate
Massey, Dan
Burris, Howard A., III
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 158 - 158

← 1 2 3 4 5 →